Abstract

No AccessJournal of UrologyAdult urology1 Oct 2006Long-Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer Michael J. Zelefsky, Heather Chan, Margie Hunt, Yoshiya Yamada, Alison M. Shippy, and Howard Amols Michael J. ZelefskyMichael J. Zelefsky Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author , Heather ChanHeather Chan Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author , Margie HuntMargie Hunt Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author , Yoshiya YamadaYoshiya Yamada Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Financial interest and/or other relationship with Varian Medical. More articles by this author , Alison M. ShippyAlison M. Shippy Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author , and Howard AmolsHoward Amols Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.06.002AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We report on the long-term results and late toxicity outcomes of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. Materials and Methods: Between 1996 and 2000 a total of 561 patients with clinically localized prostate cancer were treated with intensity modulated radiation therapy. All patients were treated to a dose of 81 Gy prescribed to the planning target volume. Prostate specific antigen relapse was defined according to the American Society for Therapeutic Radiology and Oncology consensus and Houston definitions (absolute nadir plus 2 ng/ml dated at the call). Median followup was 7 years (range 5 to 9). Results: The 8-year actuarial PSA relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the American Society for Therapeutic Radiology and Oncology definition were 85%, 76% and 72%, respectively (p <0.025). The 8-year actuarial prostate specific antigen relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the Houston definition were 89%, 78% and 67%, respectively (p = 0.0004). The 8-year actuarial likelihood of grade 2 rectal bleeding was 1.6%. Three patients (0.1%) experienced grade 3 rectal toxicity requiring either 1 or more transfusions or a laser cauterization procedure. No grade 4 rectal complications have been observed. The 8-year likelihood of late grade 2 and 3 (urethral strictures) urinary toxicities were 9% and 3%, respectively. Among patients who were potent before intensity modulated radiation therapy, erectile dysfunction developed in 49%. The cause specific survival outcomes for favorable, intermediate and unfavorable risk cases were 100%, 96% and 84%, respectively. Conclusions: These long-term results confirm our previous observations regarding the safety of high dose intensity modulated radiation therapy for clinically localized prostate cancer. Despite the application of high radiation doses, the incidence of rectal bleeding at 8 years was less than 2%. Despite the increased conformality of the dose distribution associated with intensity modulated radiation therapy, excellent long-term tumor control outcomes were achieved. References 1 : Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys2002; 53: 1097. Google Scholar 2 : Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA2005; 294: 1233. Google Scholar 3 : High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol2001; 166: 876. Link, Google Scholar 4 : Intensity modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys2004; 60: 777. Google Scholar 5 : Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys2003; 57: 384. Google Scholar 6 : Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal radiotherapy in prostate cancer–preliminary results. Int J Radiat Oncol Biol Phys2000; 48: 513. Google Scholar 7 : Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol2004; 171: 1132. Link, Google Scholar 8 : Dose-response for biochemical control among high risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys2003; 56: 1234. Google Scholar 9 : Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology2000; 55: 85. Google Scholar 10 : Long term tolerance of high dose three dimensional conformal radiotherapy in patients with localized prostate cancer. Cancer1999; 85: 2460. Google Scholar 11 : Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys2000; 48: 635. Google Scholar 12 : Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys2001; 49: 685. Google Scholar 13 : Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radioth Oncol2000; 55: 241. Google Scholar 14 : Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys1997; 39: 863. Google Scholar 15 : Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys1997; 37: 1035. Google Scholar 16 : Comparison of alternating biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external radiation therapy between 1986 and 1995. Int J Radiat Oncol Biol Phys2003; 57: 929. Google Scholar 17 : The calculated risk of secondary fatal malignancies from intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys2005; 62: 1195. Google Scholar 18 : A comparison of the integral dose from 3D conformal and IMRT techniques in the treatment of prostate cancer. Med Phys2002; 29: 1216. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byTurchan W, Cutright D, Wu T, Leng J, Dignam J, Eggener S and Liauw S (2022) Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term FollowupJournal of Urology, VOL. 207, NO. 6, (1236-1245), Online publication date: 1-Jun-2022.Zelefsky M, Goldman D, Reuter V, Kollmeier M, McBride S, Zhang Z, Varghese M, Pei X and Fuks Z (2019) Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate CancerJournal of Urology, VOL. 201, NO. 6, (1127-1133), Online publication date: 1-Jun-2019.Griebling T (2016) Re: Clinical Outcomes of Helical Tomotherapy for Super-Elderly Patients with Localized and Locally Advanced Prostate Cancer: Comparison with Patients under 80 Years of AgeJournal of Urology, VOL. 196, NO. 1, (107-107), Online publication date: 1-Jul-2016.Zumsteg Z, Spratt D, Romesser P, Pei X, Zhang Z, Kollmeier M, McBride S, Yamada Y and Zelefsky M (2015) Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate CancerJournal of Urology, VOL. 194, NO. 6, (1624-1630), Online publication date: 1-Dec-2015.Khanna A, Hu J, Gu X, Nguyen P, Lipsitz S and Palapattu G (2012) Certificate of Need Programs, Intensity Modulated Radiation Therapy Use and the Cost of Prostate Cancer CareJournal of Urology, VOL. 189, NO. 1, (75-79), Online publication date: 1-Jan-2013.Elliott S, Adejoro O, Konety B, Jarosek S, Dusenbery K and Virnig B (2012) Intensity Modulated Radiation Therapy Replaces 3-Dimensional Conformal Radiotherapy as Prostate Cancer TreatmentJournal of Urology, VOL. 187, NO. 4, (1253-1258), Online publication date: 1-Apr-2012.Kapoor D, Zimberg S, Ohrin L, Underwood W and Olsson C (2011) Utilization Trends in Prostate Cancer TherapyJournal of Urology, VOL. 186, NO. 3, (860-864), Online publication date: 1-Sep-2011. Volume 176Issue 4October 2006Page: 1415-1419 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsprostatic neoplasmsintensity-modulatedradiotherapytoxicityMetricsAuthor Information Michael J. Zelefsky Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author Heather Chan Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author Margie Hunt Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author Yoshiya Yamada Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Financial interest and/or other relationship with Varian Medical. More articles by this author Alison M. Shippy Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author Howard Amols Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York Nothing to disclose. More articles by this author Expand All Advertisement PDF downloadLoading ...